SUSAN O'BRIEN: Open Payments
NPI 1003290966 · WYOMISSING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,426 in 114 payments from 23 companies in 2025. Trend: 2023 $1,704 · 2024 $1,899 · 2025 $2,426
Food & beverage: $2,328Education: $98
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 26 | $479 |
| Insmed, Inc. | 15 | $324 |
| GENZYME CORPORATION | 11 | $247 |
| HARMONY BIOSCIENCES LLC | 12 | $200 |
| Regeneron Healthcare Solutions, Inc. | 7 | $180 |
| Merck Sharp & Dohme LLC | 9 | $142 |
| AstraZeneca Pharmaceuticals LP | 2 | $137 |
| Verona Pharma, Inc. | 4 | $120 |
| SANOFI-AVENTIS U.S. LLC | 1 | $98 |
| Axsome Therapeutics, Inc. | 5 | $83 |
Products named: DUPIXENT, Arikayce, TRELEGY ELLIPTA, NUCALA, WAKIX, ZERBAXA, Ohtuvayre, FASENRA.
Industry payments across PA — which companies pay providers there.
